Corteva Inc. Common Stock vs Enveric Biosciences Inc — how do they compare? Corteva Inc. Common Stock trades at $13.82 (market cap $9.64B), while Enveric Biosciences Inc trades at $1.51 (market cap $6.69M). The key difference: Corteva Inc. Common Stock is far larger — about 1441× Enveric Biosciences Inc's market cap, and Corteva Inc. Common Stock pays a 4.98% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Corteva Inc. Common Stock for 0 Days and Enveric Biosciences Inc for 14 Days on average.
| CTVA | ENVB | |
|---|---|---|
Market Cap | $9.64B | $6.69M |
Volume | 41,241,255 | 41,141 |
Sector | Basic Materials | Health |
52-Week High | $90.51 | $10.80 |
52-Week Low | $11.92 | $1.27 |
Typical Hold Time | 0 Days | 14 Days |
Enterprise Value | $12.15B | -$1.60M |
Dividend Yield | 4.98% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Corteva provides seeds, crop protection products, and digital tools for agriculture. Its products are used by farmers to manage crop production and protect yields.
Read more on CTVA →Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →